Stay updated with breaking news from Immatic Board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of response
ACTengine TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A), IMA203/nivolumab checkpoint
ACTengine IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with 2nd-generation
Investegate announcements from https://immatics.com/, Immatics Announces First Quarter 2022 Financial Results and Business Update
Investegate announcements from https://immatics.com/, Immatics Announces Full Year 2021 Financial Results and Corporate Update